• Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

A Good Year: FDA Approved Nine New Cancer Drugs in 2014

January 23, 2015, by NCI Staff

person holding drug vial

In 2014, the Food and Drug Administration (FDA) approved 41 drugs that had not been approved previously for any indication, the most in nearly 20 years. Of these 41 novel drugs, 9 were approved for the treatment of cancer or cancer-related conditions.

The development of new therapeutic biologics, in particular, is a trend that continues to drive cancer drug development and approval by the FDA, according to Henry Francis, M.D., of the FDA’s Center for Drug Evaluation and Research.

The FDA’s acceleration of the review process for cancer drug approval is another important factor, added Dr. Francis. Because treatment options are limited for many cancer patients with advanced disease, the FDA has implemented expedited approval procedures for cancer drugs. In some respects, the approach resembles how the agency evaluated and approved early AIDS drugs, he noted.

The following are the new drugs for cancer or cancer-related conditions approved last year by the FDA:

In February 2014, the FDA also gave full approval for ibrutinib (Imbruvica) to treat CLL. It was initially given accelerated approval in 2013 for patients with mantle cell lymphoma, a rare and aggressive type of blood cancer.

< Older Post

Bacterial Biofilms Provide Clues into Colorectal Cancer Risk

Newer Post >

Precision Medicine Initiative® and Cancer Research

Most text on the National Cancer Institute website may be reproduced or reused freely. The National Cancer Institute should be credited as the source. Please note that blog posts that are written by individuals from outside the government may be owned by the writer, and graphics may be owned by their creator. In such cases, it is necessary to contact the writer, artist, or publisher to obtain permission for reuse.

We welcome your comments on this post. All comments must follow our comment policy.

blog comments powered by Disqus